Literature DB >> 31504967

Evaluation of the Relative Performance of Pancreas-Specific MicroRNAs in Rat Plasma as Biomarkers of Pancreas Injury.

Zoltan Erdos1, John E Barnum1, Erjia Wang1, Christopher DeMaula1, Paritosh Markus Dey1, Thomas Forest1, Wendy J Bailey1, Warren E Glaab1.   

Abstract

Drug-induced pancreatic injury (DIPI) has become linked in recent years to many commonly prescribed medications from several pharmacological classes. Diagnosis is currently most often focused on identification of acute pancreatitis and generally based on subjective clinical assessment and serum amylase and lipase enzymatic activity, which have been criticized as being insufficiently sensitive and specific. The lack of novel noninvasive biomarkers of DIPI can impede the advancement of drug candidates through nonclinical development and translation into clinical settings. Pancreas-specific microRNAs (miRNAs) are currently being evaluated as biomarkers of DIPI that may outperform and/or add value to the interpretation of amylase and lipase. To assess the relative performance of these novel miRNAs, a comprehensive evaluation was conducted to determine the sensitivity and specificity of detecting DIPI in rats. Four miRNAs were evaluated (miR-216a-5p, miR-216b-5p, miR-217-5p, and miR-375-3p) in plasma from 10 studies in which rats were treated with known pancreatic toxicants to assess sensitivity, and from 10 different studies in which toxicity was evident in tissues other than pancreas to assess specificity. The candidate miRNA biomarker performance was compared with amylase and lipase, and receiver operator characteristics (ROC) were determined. Analysis of ROCs demonstrated that all four miRNAs outperformed amylase and lipase in monitoring acute pancreatic injury defined as acinar cell degeneration/necrosis. Specifically, miR-217-5p had the highest performance among all biomarkers assessed. The increased sensitivity and specificity of these miRNAs support their use as biomarkers of DIPI, thereby adding value to the interpretation of amylase and lipase measurements in nonclinical studies. The potential for miRNAs to serve as translational biomarkers in the clinic for the monitoring of DIPI is also supported by this investigation.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Biomarker; Pancreas; miR-217; miRNA

Mesh:

Substances:

Year:  2020        PMID: 31504967     DOI: 10.1093/toxsci/kfz184

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  7 in total

1.  The Role of miR-217-5p in the Puromycin Aminonucleoside-Induced Morphological Change of Podocytes.

Authors:  Osamu Ishibashi; Mika Hayashi; Aya Horikawa; Hitoshi Owada; Ryotaro Miyamoto; Naoya Mizukami; Takashi Inui
Journal:  Noncoding RNA       Date:  2022-06-08

2.  miR‑217‑5p regulates myogenesis in skeletal muscle stem cells by targeting FGFR2.

Authors:  Menghai Zhu; Gang Chen; Yi Yang; Jiantao Yang; Bengang Qin; Liqiang Gu
Journal:  Mol Med Rep       Date:  2020-05-07       Impact factor: 2.952

3.  MicroRNAs as systemic biomarkers to assess distress in animal models for gastrointestinal diseases.

Authors:  Simone Kumstel; Heike Janssen-Peters; Ahmed Abdelrahman; Guanglin Tang; Ke Xiao; Nicole Ernst; Edgar Heinz Uwe Wendt; Rupert Palme; Nico Seume; Brigitte Vollmar; Thomas Thum; Dietmar Zechner
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

Review 4.  Systems analysis of miRNA biomarkers to inform drug safety.

Authors:  Amy L Schofield; Joseph P Brown; Jack Brown; Ania Wilczynska; Catherine Bell; Warren E Glaab; Matthias Hackl; Lawrence Howell; Stephen Lee; James W Dear; Mika Remes; Paul Reeves; Eunice Zhang; Jens Allmer; Alan Norris; Francesco Falciani; Louise Y Takeshita; Shiva Seyed Forootan; Robert Sutton; B Kevin Park; Chris Goldring
Journal:  Arch Toxicol       Date:  2021-09-12       Impact factor: 5.153

5.  Liver injury changes the biological characters of serum small extracellular vesicles and reprograms hepatic macrophages in mice.

Authors:  Xiu-Fang Lv; An-Qi Zhang; Wei-Qi Liu; Min Zhao; Jing Li; Li He; Li Cheng; Yu-Feng Sun; Gang Qin; Peng Lu; Yu-Hua Ji; Ju-Ling Ji
Journal:  World J Gastroenterol       Date:  2021-11-21       Impact factor: 5.742

6.  A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers.

Authors:  Kseniya Khamina; Andreas B Diendorfer; Susanna Skalicky; Moritz Weigl; Marianne Pultar; Teresa L Krammer; Catharine Aquino Fournier; Amy L Schofield; Carolin Otto; Aaron Thomas Smith; Nina Buchtele; Christian Schoergenhofer; Bernd Jilma; Bernhard J H Frank; Jochen G Hofstaetter; Regina Grillari; Johannes Grillari; Klemens Ruprecht; Christopher E Goldring; Hubert Rehrauer; Warren E Glaab; Matthias Hackl
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

7.  A robust biostatistical method leverages informative but uncertainly determined qPCR data for biomarker detection, early diagnosis, and treatment.

Authors:  Wei Zhuang; Luísa Camacho; Camila S Silva; Michael Thomson; Kevin Snyder
Journal:  PLoS One       Date:  2022-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.